Sign in
TerminatedPhase 1

Phase I Study of Radiolabeled OTSA101-DTPA in Patients With Relapsed or Refractory Synovial Sarcoma

Key facts

Who runs it
OncoTherapy Science, Inc.
Where
Japan3 sites in 1 countryChoose a country to see its sites
Trial code
Status
Terminated
Phase
Phase 1
People taking part
12 people enrolled
Started
10 Jan 2020
Ended
11 Jan 2024
Type of study
Interventional
Treatments tested
  • OTSA101-DTPA-111In
  • OTSA101-DTPA-90Y
Record updated
2 February 2024
Why it stopped
Some of the raw materials for the investigational drug are difficult to obtain and expensive.

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 23 criteriaShow less

Who can take part

  • Patients with a documented relapsed or refractory synovial sarcoma after standard chemotherapy
  • Patients ≥18 years of age at the time of obtaining informed consent
  • Patients with an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1
  • Patients with measurable lesion
  • Patients not received any anti-malignancy agent or specified surgical intervention within 28 days or specified radiotherapy within 14 days prior to study registration
  • Patients without any clinically significant laboratory abnormality
  • Patients with adequate heart function as measured by echocardiography or multiple gated acquisition scan (MUGA)
  • Patients with adequate pulmonary function as measured by pulmonary function tests
  • Patients who are either not of childbearing potential or who agree to use a contraception method during the study and for 12 months after the last dose of study drug
  • Patients must be able to understand and be willing to sign a written informed consent

Who cannot take part

  • Patients with documented concurrent malignancy
  • Patients with myocardial infarction (MI) within 6 months prior to study registration
  • Patients with any infection requiring systemic treatment
  • Patients with a known history of autoimmune diseases
  • Patients with uncontrolled diseases
  • Patients with any disease requiring continuous systemic administration of steroids or immunosuppressants
  • Patients with evidence of active HBV, HCV or HIV infection
  • Patients with psychiatric disorders and is considered to have difficulty to study participation
  • Patients with a known history of hypersensitivities to antibody agents or serum albumin agents
  • Patients with brain metastasis with clinical symptoms
  • Patients with lung inflammation or pulmonary fibrosis
  • Pregnant or breastfeeding female patients, or female patients with suspected pregnancy
  • Patients who are participating any other investigational treatments during the study

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The purpose of this study is to evaluate safety and pharmacokinetics as well as the biodistribution of OTSA101-DTPA-111In and to evaluate the safety of intravenous administration of OTSA101-DTPA-90Y.

The group in the trial

  • Single Study Arm, no competitorTreatment being tested

    Treatment: OTSA101-DTPA-111In and OTSA101-DTPA-90Y

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Safety Study of Radiolabeled (111In or 90Y) OTSA101-DTPA, an Anti-Frizzled Homolog 10 (FZD10) Monoclonal Antibody, to Evaluate Safety and Pharmacokinetics in Patients With Relapsed or Refractory Synovial Sarcoma
Publications
Record updated
2 February 2024